NCT06494124 Efficacy and Safety of tACS vs tDCS in Schizophrenia
| NCT ID | NCT06494124 |
| Status | Recruiting |
| Phase | — |
| Sponsor | All India Institute of Medical Sciences, Bhubaneswar |
| Condition | Schizophrenia |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2024-04-03 |
| Primary Completion | 2026-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 90 participants in total. It began in 2024-04-03 with a primary completion date of 2026-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial aims to compare the efficacy and safety of transcranial Alternating current stimulation (tACS) vs. transcranial Direct current stimulation (tDCS) vs. sham stimulation in chronic schizophrenia. The main question it aims to answer is: • In comparison to tDCS, can tACS improve the clinical outcome of patients with chronic schizophrenia? Participants will be randomised into 3 groups receiving either tDCS, tACS or sham stimulation and changes in psychopathology and neuro-cognition with the interventions will be compared within and between the groups. The primary outcome measure is the Positive and Negative Syndrome Scale (PANSS), while secondary outcome measures are the Auditory Hallucination Rating Scale (AHRS), Brief Cognitive Assessment Tool for Schizophrenia (B-CATS), and Global Assessment of Functioning (GAF).
Eligibility Criteria
Inclusion Criteria: 1. Diagnosis of Schizophrenia as per ICD-10 DCR for more than 2 years 2. Moderate-severe symptoms (PANSS score \> 75 and/or CGI-SCH score\>4) \[24\] 3. On stable dosing of antipsychotic medications (no changes in medication or doses for 1 month prior to enrolment) 4. Both sexes; Age range: 18-60 years 5. Right-handed 6. Written informed consent by the patient Exclusion Criteria: 1. Features suggestive of psychiatric emergency (for example: suicidal risk, catatonia, prolonged nutritional deprivation) or others (for example: aggression or excitement) 2. Any contraindication to tDCS procedure: Metal in the head, Implanted brain medical devices, Local lesion or injury in the scalp / head 3. Co-morbid neurological disease 4. Left Handed
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06494124 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Schizophrenia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06494124 currently recruiting?
Yes, NCT06494124 is actively recruiting participants. Contact the research team at brm1678@gmail.com for enrollment information.
Where is the NCT06494124 trial being conducted?
This trial is being conducted at Bhubaneswar, India.
Who is sponsoring the NCT06494124 clinical trial?
NCT06494124 is sponsored by All India Institute of Medical Sciences, Bhubaneswar. The trial plans to enroll 90 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.